1. Home
  2. ZSQR vs KROS Comparison

ZSQR vs KROS Comparison

Compare ZSQR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$3.91

Market Cap

204.6M

Sector

Finance

ML Signal

N/A

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

N/A

Current Price

$11.17

Market Cap

206.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZSQR
KROS
Founded
2022
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
206.0M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ZSQR
KROS
Price
$3.91
$11.17
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $19.83
AVG Volume (30 Days)
★ 375.9K
148.6K
Earning Date
08-13-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
50.27
★ 146.00
EPS
★ N/A
N/A
Revenue
$1,363,045.00
★ $243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.11
$9.69
52 Week High
$16.62
$22.55

Technical Indicators

Market Signals
Indicator
ZSQR
KROS
Relative Strength Index (RSI) 58.36 52.16
Support Level $2.81 $10.59
Resistance Level $4.64 $11.69
Average True Range (ATR) 0.47 0.43
MACD 0.26 -0.02
Stochastic Oscillator 79.36 48.15

Price Performance

Historical Comparison
ZSQR
KROS

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: